Skip to main content
Fagron N.V. logo

Fagron N.V. — Investor Relations & Filings

Ticker · FAGR ISIN · BE0003874915 LEI · 549300TRKRUFK2RRG779 BR Manufacturing
Open in API
Filings indexed 1,987 across all filing types
Latest filing 2026-03-06 Annual Report
Country BE Belgium
Listing BR FAGR

About Fagron N.V.

https://fagron.com/

Fagron N.V. is a global company active in pharmaceutical compounding, focusing on the delivery of personalized medicine. The company optimizes and innovates compounding to widen the therapeutic options for prescribers worldwide. Fagron develops, markets, and distributes pharmaceutical raw materials, equipment, and specially formulated vehicles and bases, such as the Pentravan® transdermal base and the SyrSpend® range of oral suspending vehicles. Its primary customers are hospitals, pharmacies, and clinics. The company also operates in the field of genomics to further support personalized healthcare solutions.

Recent filings

Filing Released Lang Actions
Fagron Jaarverslag 2025 ESEF.xbri
Annual Report Classification · 100% confidence The document is titled 'Jaarverslag 2025' (Annual Report 2025) and contains a comprehensive structure including a CEO statement, financial performance, governance, consolidated financial statements, and sustainability disclosures. It is clearly the full annual report for the fiscal year 2025, not an announcement or a summary. FY 2025
2026-03-06 Dutch
Fagron completes acquisition of Vepakum
M&A Activity Classification · 100% confidence The document is a press release announcing the successful completion of an acquisition (Vepakum) by Fagron. It details the regulatory approval process and the strategic rationale for the acquisition. Since this document specifically concerns merger and acquisition activity, it falls under the 'M&A Activity' category.
2026-03-03 Dutch
Fagron completes acquisition of Vepakum
M&A Activity Classification · 100% confidence The document is a press release announcing the successful completion of an acquisition (Vepakum). It details the regulatory clearance and the strategic rationale for the transaction. Since it specifically concerns a merger/acquisition activity, it falls under the M&A Activity category.
2026-03-03 English
Fagron completes acquisition of Vepakum.pdf
M&A Activity Classification · 100% confidence The document is a press release announcing the successful completion of an acquisition (Vepakum). It details the regulatory clearance and the strategic rationale for the transaction. Since it specifically concerns a merger/acquisition activity, it falls under the M&A Activity category.
2026-03-03 English
Fagron voltooit overname van Vepakum .pdf
M&A Activity Classification · 100% confidence The document is a press release announcing the successful completion of an acquisition (Vepakum) by Fagron. It details the regulatory approval process and the strategic rationale for the acquisition. Since this document specifically concerns merger and acquisition activity, it falls under the 'M&A Activity' category.
2026-03-03 Dutch
Disclosure of a transparency notification from AOC Pharma S.à r.l.
Major Shareholding Notification Classification · 100% confidence The document is a press release titled 'Disclosure of a transparency notification from AOC Pharma S.à r.l.' regarding a change in major shareholding (crossing the 10% threshold). This falls under the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels.
2026-03-02 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.